AG-221 (Enasidenib) | B1070

AG-221(Enasidenib) is a potent, selective, and reversible inhibitor of mutant IDH2 (isocitrate dehydrogenase type 2). It specifically inhibits IDH2 in the mitochondria, blocking the formation of oncometabolite 2-hydroxyglutarate (2HG). In in vitro studies, AG-221 reduces 2-HG levels by >90%, reverses histone and DNA hypermethylation, and induces cellular differentiation in leukemia cell models.

AG-221(Enasidenib) is a potent, selective, and reversible inhibitor of mutant IDH2 (isocitrate dehydrogenase type 2). It specifically inhibits IDH2 in the mitochondria, blocking the formation of oncometabolite 2-hydroxyglutarate (2HG).

B1070 | AG-221 (Enasidenib) DataSheet

Alternate Name/Synonyms: 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol

Appearance: White to off-white solid

Formulation: N/A

CAS Number: 1446502-11-9

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₁₉H₁₇F₆N₇O

Molecular Weight: 473.38

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO (>30 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent IDH2 (Isocitrate dehydrogenase 2) inhibitor

MDL Number:

PubChem CID: 89683805

SMILES: CC(C)(CNC1=NC(=NC(=N1)NC2=CC(=NC=C2)C(F)(F)F)C3=NC(=CC=C3)C(F)(F)F)O

InChi: InChI=1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32)

InChi Key: DYLUUSLLRIQKOE-UHFFFAOYSA-N